RenovoRx Reports Positive Data From Phase III Trial Interim Analysis Of RenovoGem Therapy
RenovoRx, Inc. (RNXT) said it will present detailed, open label, planned Phase III interim data analysis of its RenovoGem therapy for pancreatic cancer patients at the American Association for Cancer Research Annual Meeting.